Enacts the NYS PPE resilience & manufacturing act
A11496 would enact the “NYS PPE resilience & manufacturing act” and add a new section to the state finance law governing how certain state-funded health care entities buy personal protective equipment. The bill requires those entities to purchase PPE manufactured in New York State for contracts over $50,000, so long as the products are available and meet required specifications for form, function, and utility.
The measure defines covered entities broadly to include state agencies, SUNY and CUNY, hospitals and nursing homes receiving state funding, and community health centers, diagnostic and treatment centers, and federally qualified health centers receiving state aid or grants. It also authorizes the commissioner to waive the in-state purchasing requirement if the needed PPE is not produced in New York in any quantity or if New York-made PPE costs more than comparable out-of-state PPE by more than 20 percent. Any waiver must be posted on the Office of General Services website for at least 15 days before the contract is finalized.
The bill would create a new state procurement preference for New York-manufactured PPE in state-funded health care purchasing, affecting state agencies, public universities, and a range of publicly supported health care providers. It would amend the state finance law by adding section 165-b and would likely influence contracting practices, vendor eligibility, and procurement review for PPE purchases above the $50,000 threshold. The waiver and public-comment provisions would also add an administrative oversight and transparency layer to the procurement process.
Based on the available record, the bill appears to have been introduced and referred to committee without recorded floor debate or votes, so there is no documented partisan or public sentiment in the provided materials. The structure of the bill suggests a policy goal of strengthening supply-chain resilience and supporting in-state manufacturing, which is generally framed as a positive economic and public-health measure. However, the inclusion of a cost-based waiver indicates an effort to balance that goal against procurement flexibility and fiscal concerns.
The main points of potential contention are likely to be the in-state purchasing mandate and its effect on cost and sourcing flexibility. Supporters would likely emphasize supply-chain resilience, domestic manufacturing, and state economic development, while opponents or procurement officials may question whether the requirement could raise costs, limit competition, or complicate timely PPE acquisition. The waiver standard—especially the 20 percent price threshold and the requirement that PPE be unavailable in-state in any quantity—appears designed to address those concerns, but it may still be debated as either too restrictive or too permissive.